Recombinant allergens The present and the future

被引：25

作者：

Jutel, Marek ^{[1
]}

Solarewicz-Madejek, Katarzyna ^{[1
]}

Smolinska, Sylwia ^{[1
]}

机构：

[1] Wroclaw Med Univ, Dept Clin Immunol, Wroclaw, Poland

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2012年 / 8卷 / 10期

关键词：

allergy; allergen-specific immunotherapy; recombinant allergens; hypoallergens; vaccines; HOUSE-DUST MITE; BIRCH POLLEN ALLERGEN; COMPONENT-RESOLVED DIAGNOSTICS; T-CELL PEPTIDES; GRASS-POLLEN; CROSS-REACTIVITY; FOLLOW-UP; IMMUNOTHERAPY; CAT; EPITOPE;

D O I：

10.4161/hv.22064

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Allergen specific immunotherapy (SIT) is the only known causative treatment of allergic diseases. Recombinant allergen-based vaccination strategies arose from a strong need to both to improve safety and enhance efficacy of SIT. In addition, new vaccines can be effective in allergies including food allergy or atopic dermatitis, which poorly respond to the current treatment with allergen extracts. A number of successful clinical studies with both wild-type and hypoallergenic derivatives of recombinant allergens vaccines have been reported for the last decade. They showed high efficacy and safety profile as well as very strong modulation of T and B cell responses to specific allergens.

引用

页码：1534 / 1543

页数：10

共 72 条

[1] IgE-binding epitopes: a reappraisal [J].